Extended Research →
Verdict, decision matrix, deep dives, sourcing notes & full sources

Dexedrine

Emerging

Pure d-amphetamine — same active drug as Vyvanse but without prodrug protection, slightly cleaner peripheral profile than Adderall (no… | Pharmaceutical · Oral

Aliases (7)
Dextroamphetamine · Dextroamphetamine Sulfate · Zenzedi · ProCentra · Dexedrine Spansule · d-amphetamine · (S)-(+)-amphetamine
TYPICAL DOSE
5-10 mg
ROUTE
Oral (tablet)
CYCLE
if used
STORAGE
Room temp; original container
Did you know? You can suggest edits to improve this compound's information.
Submitted via email — no account required.
Suggest an edit
Brand options5 known
DextroamphetamineDextroamphetamine SulfateZenzediProCentraDexedrine Spansule

StatusSchedule II (US DEA) | Schedule 8 (Australia) | Class B (UK) | Class III (Canada CDSA)

Overview TL;DR

Pure d-amphetamine — same active drug as Vyvanse but without prodrug protection, slightly cleaner peripheral profile than Adderall (no L-isomer cardiovascular load). For 20yo Dylan with no diagnosis: SKIP-FOR-NOW. Same brain-dev / age reasoning that rules out other amphetamines applies here. STRONG-CANDIDATE only if a clinical narcolepsy or ADHD diagnosis is established and a prescriber recommends a classical stim.

Mechanism of action

Dextroamphetamine is the (S)-(+)-enantiomer of amphetamine — the more potent CNS-active half. Pure d-amphetamine, no levoamphetamine. This is what makes Dexedrine pharmacologically distinct from Adderall (3:1 mixed d:l salts) and downstream-identical to Vyvanse (which is a lysine-bonded prodrug that the body cleaves into d-amphetamine).

Triple action — how amphetamines actually move dopamine:

  1. TAAR1 agonism (intracellular). Amphetamine enters monoamine neurons via DAT/NET. Inside, it activates trace amine-associated receptor 1 (TAAR1), which triggers PKA/PKC phosphorylation of DAT → DAT internalizes off the membrane AND reverses its transport direction. Dextroamphetamine is a 3-4× more potent TAAR1 agonist than levoamphetamine, which is the molecular reason d-amphetamine produces more CNS stimulation per mg.
  2. VMAT2 inhibition + cytoplasmic flooding. Amphetamine displaces dopamine, NE, and serotonin from synaptic vesicles into the cytoplasm. Cytoplasmic monoamine concentrations spike.
  3. Reverse transport (efflux). With DAT/NET now running in reverse, the cytoplasmic monoamine pool floods out into the synapse — the opposite of how transporters normally work. This is "forced release," distinct from reuptake inhibition (cocaine, methylphenidate) or eugeroic mechanisms (modafinil).

Mild MAO inhibition at high doses adds further amplification.

Why "cleaner than Adderall" is mechanistically real, not just marketing:

  • Levoamphetamine (the 25% in Adderall that's NOT in Dexedrine) is the weaker CNS agent but the stronger peripheral sympathomimetic. L-amphetamine has slightly higher cardiovascular and smooth-muscle effects per mg.
  • Strip out the L-isomer → fewer peripheral effects (jitters, jaw tension, vasoconstriction, BP spike) per unit of central dopamine release. This is the mechanism behind anecdotal reports that Dexedrine "feels cleaner" or "less anxious" than Adderall.
  • The effect is real but modest — both drugs still hit cardiovascular system meaningfully, both still carry the FDA black-box for sudden cardiac death.

vs Vyvanse: Same active drug post-metabolism, different release kinetics. Vyvanse must be cleaved by GI peptidases (lysine bond) before any d-amphetamine appears in plasma → slow ramp, no IV/snort potential, lower abuse liability. Dexedrine IR delivers d-amphetamine directly → fast onset, higher peak, more euphoric, more abusable.

Pharmacokinetics Approximate
t½: 10-12 hr (varies with urinary pH — alkaline urine prolongs
100% 50% 0% 0 14h 28h 41h 2d Peak

Approximate decay curve drawn from the half-life mention(s) in the source notes. Real PK data not yet ingested per compound.

Quality indicators4 checks
FDA-approved manufacturer
NDC code on the bottle matches FDA registration. Generic OK; backyard not OK.
Brand vs generic listed
Pharmacy fills should disclose substitution. AB-rated generics are bioequivalent.
Tamper-evident packaging
Pharmacy seal intact, lot number + expiry visible on the bottle and the box.
!
Schedule labeling correct
C-II / C-IV warnings on label match the medication; report any mismatch to the pharmacist.
What to expect Generic
  1. 1
    Day 1
    PK-driven acute peak per administration. Verify dose tolerated.
  2. 2
    Week 1
    Steady-state reached for most daily-dosed pharma.
  3. 3
    Week 2-4
    Therapeutic effect established; titration window if needed.
  4. 4
    Long-term
    Periodic monitoring per drug class (labs, BP, ECG as applicable).
Side effects + safety Tabbed view

Common (>10% users)

  • Appetite suppression (often significant — bigger issue for Dylan's MMA training calorie needs)
  • Insomnia / delayed sleep onset (incompatible with Dylan's late-chronotype migration plan)
  • Dry mouth
  • Increased BP and HR (smaller than Adderall on average, but real)
  • Headache
  • Weight loss
  • Anxiety / nervousness
  • Mood elevation that may feel artificial

Less common (1-10%)

  • Bruxism (jaw clenching) — less than Adderall but present
  • Tachycardia / palpitations
  • Vasoconstriction (cold extremities, Raynaud-like)
  • Tics / motor stereotypies (especially in adolescents)
  • Erectile dysfunction at higher doses
  • Mood lability / irritability on taper
Interactions8 compounds
  • L-tyrosineSynergistic
    substrate replenishment for sustained dopamine synthesis; theoretical basis for blunting late-day crash. Modest evidence.
  • MagnesiumSynergistic
    counters NMDA-glutamate excitotoxicity, may reduce bruxism and anxiety.
  • L-theanineSynergistic
    anxiolytic counter to peripheral stim load.
  • MAOIs (selegiline, phenelzine, tranylcypromine, moclobemide)Avoid
    hypertensive crisis risk. Even low-dose (1-2.5 mg) selegiline carries this concern. Hard contraindication.
  • SSRIs / SNRIsAvoid
    serotonin syndrome risk plus CYP2D6 inhibition (fluoxetine, paroxetine especially) elevates d-amphetamine plasma levels.
  • BupropionAvoid
    additive dopaminergic + seizure threshold lowering + CYP2D6 inhibition.
  • Other stimulantsAvoid
    (Adderall, Vyvanse, methylphenidate, modafinil at high dose) — additive cardiovascular load + dopamine downregulation.
  • AlcoholAvoid
    masks intoxication, cardiovascular load.
References13 sources
Was this helpful?
Your feedback shapes what we research deeper.
Continue: Extended Research →
Our verdict, decision matrix, deep dives, controversies, sources